platoseedplatoseed
Artificial intelligence for drug discovery.
Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge machine learning algorithms. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.
Numerion Labs is an AI-driven platform and program ecosystem focused on discovering novel, drug-like molecules through machine learning to advance small-molecule drug discovery, with emphasis on immune and inflammatory diseases.
An AI superplatform that explores chemical space to identify novel, drug-like molecules unseen by others. It powers programs built on the platform to deliver first- and best-in-class potential for immune and inflammatory diseases, supported by a world-class team of scientists and engineers dedicated to redefining how small-molecule drugs are discovered.
Who it’s for: Pharmaceutical companies, biotech startups, and research organizations focused on small-molecule drug discovery, particularly in immune and inflammatory diseases.
Leveraging AI to revolutionize the physical sciences, Alex Levy is the CEO and co-founder of Atmo, the leading company integrating AI into global weather forecasting. Previously, he co-founded Atomwise (W15), a pioneering AI company in small molecule drug discovery, boasting over 800 active programs and $1 billion in pharmaceutical partnerships. An alumnus of the University of Toronto, he began his career by leading a computer vision research lab within the Computer Science Department.
Formerly “Atomwise” · why startups rename →
Personalized drug discovery for blood cancer.
We use human data and AI to develop better drugs faster.
